Abstract
Rising to the challenges of biologics development in this period of disruptive change requires an appreciation for the
science, technology, and market forces driving the transformation and a willingness to adopt strategies that align with these
changes.
For most pharmaceutical and biotech companies, this means identifying trusted partners who can provide access
to innovative technologies and methodologies, sufficient manufacturing capacity for growing biologics demand, deep expertise
in navigating regulatory channels, and the operational efficiencies needed to accelerate speed to market.
This report
provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly
